Udg Healthcare Plc operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Udg Healthcare Plc with three other
drug stores in Europe:
Zur Rose Group AG
sales of 1.21 billion Swiss Francs [US$1.22 billion]
of which 56%
Dermapharm Holding SE
(572.42 million Euro [US$633.91 million]
of which 58%
was Pharmaceuticals and other products), and
based in Finland
(1.55 billion Euro [US$1.72 billion]
of which 171%
Udg Healthcare Plc reported sales of 1.10 billion Euro (US$1.22 billion)
September of 2018.
a very small
increase of 0.6%
versus 2017, when the company's sales were 1.10 billion Euro.
This was the third consecutive year of growth at Udg Healthcare Plc.
Sales of Ashfield saw an increase
that was more than double the company's growth rate: sales were up
4.7% in 2018, from
739.63 million Euro to 774.09 million Euro.
Not all segments of Udg Healthcare Plc experienced an increase in sales in 2018:
sales of Aquilant fell 19.8% to 69.48 million Euro.
Udg Healthcare Plc also experienced decreases in sales in
Sharp (down 3.9% to 261.34 million Euro)